2seventy bio’s (TSVT) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research note published on Saturday,Weiss Ratings reports.

2seventy bio Trading Up 7.0 %

Shares of NASDAQ TSVT opened at $2.61 on Friday. 2seventy bio has a 12-month low of $2.35 and a 12-month high of $6.40. The stock’s fifty day simple moving average is $3.24 and its two-hundred day simple moving average is $4.14. The stock has a market capitalization of $134.65 million, a PE ratio of -1.40 and a beta of 1.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. SkyView Investment Advisors LLC boosted its stake in 2seventy bio by 25.0% in the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock valued at $48,000 after acquiring an additional 2,500 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of 2seventy bio in the 3rd quarter worth $25,000. XTX Topco Ltd grew its stake in 2seventy bio by 61.1% during the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock worth $115,000 after buying an additional 9,257 shares during the last quarter. Bank of New York Mellon Corp increased its position in 2seventy bio by 5.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company’s stock valued at $758,000 after buying an additional 10,077 shares in the last quarter. Finally, Readystate Asset Management LP purchased a new stake in 2seventy bio in the third quarter valued at about $53,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.